MemoryLinc® : ncRNA multiplex RT-qPCR IVD assay kit
Neurodegenerative Diseases are multifactorial complex disorders and genetics play a crucial role in their development. The challenge of their early detection and precise diagnosis is ever more pressing. Traditional diagnostic methods are often invasive, such as cerebrospinal fluid (CSF) sampling, or costly, such as PET scans. Thus, the demand for a less invasive, blood-based test that can accurately diagnose Neurodegenerative Diseases early, aid in drug development, and inform treatment choices is significant.
The MemoryLinc® ncRNA multiplex RT-qPCR IVD assay kit is a reverse transcription (RT) quantitative polymerase chain reaction (qPCR) test for the in vitro quantitative determination of non-coding RNA (ncRNA) signature in plasma-EDTA or whole blood (human) to aid in the diagnosis of Alzheimer’s Disease (AD) in conjunction with clinical findings and the results of laboratory testing. MemoryLinc® is intended to be used to assess plasma or whole blood samples on QuantStudio 5 Dx real-time PCR system.
Features and benefits
Memorylinc® is a first-in-class blood test leveraging neurodegenerative ncRNA biomarkers
crafted in a high-quality setting and leading to highly reproducible results that can be used to diagnose Alzheimer's at an early stage.
Simplified workflow
Optimize your biomarker projects and development programs
From concept to regulatory qualification, with significant experience in each step, we provide steadfast support across diverse areas
We are committed to improve disease outcome, therapeutic decisions and generate savings in healthcare
through biomarker discovery, development and regulatory qualification.